Drug Trial Radar · NCT04118114
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Sep 3, 2019
Primary completion
Oct 17, 2025
Study completion Oct 17, 2025
Sponsor
- Lead sponsor
- National Cancer Centre, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- INTRA-IMMUSG PRIVATE LIMITED
- First posted
- Oct 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy. Approximately 30 patients will be recruited with \~10 gastric cancers and \~10 hepatocellular carcinomas. Patients who have received at least 1 dose of PRL3-ZUMAB will be evaluable for toxicity and efficacy. PRL3-ZUMAB will be given IV every 2 weeks for up to 12 infusions in the absence of unmanageable toxicities or disease progression. Patients who are benefitting from the treatment may continue on PRL3-ZUMAB beyond 12 infusions with the agreement of the study drug provider. PRL3-ZUMAB at the RP2D in tumour types enriched for known PRL-3 expression for efficacy and tolerability will be evaluated. There will also be in depth molecular profiling of tissues in patients who have an objective response or prolonged disease stabilization to identify predictive/selection biomarkers as well as evaluation of the oncogenic signaling modulation and immunomodulation by PRL3-ZUMAB and its potential for future combination with other targeted therapies or immunotherapy.
Conditions
- Gastric Cancer
- Hepatocellular Carcinoma
- Advanced Solid Tumor
Interventions
PRL3-zumabDrug
IV administration every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: From start of treatment to first occurence of disease progression or death, up to 2 years
- Number of patients that do not have disease progression at 16 weeks from start of treatmentTime frame: 16 weeks after start of treatment
- Treatment related adverse events rateTime frame: From start of treatment to 30 days after last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center Singapore
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.